MAA, EDMA and TRIM were purified before use by using a hydroquinone inhibitor remover column (Sigma-Aldrich, catalog no. 306312).
In this study, we identified potential protein inhibitors by column-chromatography based purification of inhibitory fractions followed by 3D gel electrophoresis and Nano-HPLC-ESI-Q-TOF mass spectrometry.
The corrective effect of hNE in knockout mice was fully abolished in the presence of EPI-hNE4, a Kunitz-type specific inhibitor of hNE (21) (column 10).
As shown in Fig. 4B, Y27632 reduced the invasiveness of cen3tel cells at all three different stages (black columns), while the metalloprotease inhibitor did not affect it (grey columns).
Methyl methacrylate (MMA) (Lancaster) was purified using a basic alumina column (to remove inhibitor), followed by deoxygenation by bubbling argon gas through the solution ∼1 h) and stored under argon in the freezer (−10 °C).
Recombinant Mps1 protein was purified in lysis buffer (50 mM NaH2PO4 pH 7.5, 300 mM NaCl, 10% glycerol, 1 mM DTT, 1 mM PMSF, 1X Complete EDTA-free protease inhibitor cocktail (Roche, Canada)) with column packed with Ni-NTA Sepharose (GE Healthcare, UK).
Simultaneously, a different final concentration of other HCV inhibitors was added to each column of the plate.
tert-Butyl acrylate (t BA, 98%, Fluka) was passed through a basic alumina column to remove the inhibitor, and then distilled under reduced pressure before polymerization.
The ED50 values were calculated using the amount of viable cells in the absence of vincristine but in the presence of PKC inhibitor as 100% (values in A columns) or the amount of viable cells in the absence of vincristine and PKC inhibitor (values in B columns).
Excess inhibitor was then removed using desalting columns packed with Sephadex G-25 (PD-10, GE Healthcare), and the completion of complex formation was confirmed by MALDI-MS.
